Physician
Reece, Timmothy
Reece, Timmothy was paid $1.60M by Medicaid between Jul 2020 and Dec 2024, across 57 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 28% of everything it billed.
33Billing provider infoREECE, TIMMOTHY
WHITE HALL, AR 71602
WHITE HALL, AR 71602
33aNPI1679794762assigned 05/02/2007
33bProvider typeFamily Medicine Physician
28Total paid$1.60M
24GClaims51,207
24DCodes billed57
24AFirst – last monthJul 2020 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Arkansas
Rank by total paid#12 of 437
Median peer was paid$70K
This provider vs. median23×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 255 | $1K | |
| 2021 | 14,338 | $360K | |
| 2022 | 13,554 | $506K | |
| 2023 | 9,856 | $390K | |
| 2024incomplete | 13,204 | $338K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 28% | 14,104 | 11,274 | $442K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 24% | 4,037 | 3,307 | $386K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 4,175 | 3,476 | $189K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 9.5% | 3,820 | 3,075 | $151K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 7.2% | 1,345 | 1,180 | $114K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 5.4% | 2,814 | 1,924 | $86K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.8% | 1,462 | 1,272 | $61K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 2.0% | 733 | 647 | $33K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.0% | 353 | 316 | $16K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 349 | 277 | $14K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 253 | 226 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 952 | 465 | $10K |
45 more codes
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 288 | $10K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,223 | $9K |
| 80053 | Comprehensive metabolic panel | <1% | 746 | $8K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 724 | $7K |
| 87428 | <1% | 89 | $6K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 121 | $5K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 397 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 311 | $4K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 236 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 99 | $3K |
| 84480 | <1% | 189 | $3K | |
| T1502 | Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit | <1% | 1,579 | $2K |
| 84439 | <1% | 208 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 994 | $2K |
| 90686 | <1% | 255 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 118 | $2K |
| 90633 | <1% | 146 | $1K | |
| 74018 | <1% | 60 | $1K | |
| 80061 | Lipid panel | <1% | 100 | $1K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 741 | $996.21 |
| 90734 | <1% | 94 | $745.68 | |
| 90649 | <1% | 69 | $652.40 | |
| 90670 | <1% | 86 | $630.96 | |
| 81003 | <1% | 1,064 | $607.57 | |
| 90619 | <1% | 49 | $538.74 | |
| 90647 | <1% | 65 | $516.24 | |
| 90710 | <1% | 61 | $468.44 | |
| 90715 | <1% | 49 | $434.92 | |
| 90723 | <1% | 50 | $363.28 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,392 | $314.74 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 175 | $294.58 |
| 82962 | <1% | 88 | $240.12 | |
| 71045 | Radiologic examination, chest; single view | <1% | 22 | $237.20 |
| 90648 | <1% | 12 | $185.40 | |
| 87807 | <1% | 15 | $169.13 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17 | $166.44 |
| 90696 | <1% | 13 | $105.16 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 17 | $36.18 |
| 3078F | 0% | 1,653 | $0.00 | |
| 3077F | 0% | 105 | $0.00 | |
| 3079F | 0% | 406 | $0.00 | |
| 3075F | 0% | 178 | $0.00 | |
| 3080F | 0% | 44 | $0.00 | |
| 3074F | 0% | 1,830 | $0.00 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 632 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.